ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

Thomas Powles, MD
Published: Sunday, Nov 19, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles.

CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).
 


Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles.

CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x